section name header

Indications

High Alert

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema.

Derm: rash, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS (TEN).

EENT: nasal congestion.

Endo: hyperglycemia, hypoglycemia.

F and E: hyponatremia.

GI: liver enzymes, abdominal pain, colitis/diarrhea, hepatotoxicity, nausea, vomiting, INTESTINAL PERFORATION, stomatitis.

Hemat: anemia, neutropenia, thrombocytopenia.

Metab: hypertriglyceridemia.

MS: arthralgia, pain.

Neuro: fatigue, headache, insomnia, weakness.

Resp: cough, dyspnea, PNEUMONITIS.
Misc: chills, fever, infection, night sweats, ANAPHYLAXIS.

Interactions

Drug-Drug:

Availability

Route/Dosage

US Brand Names

Zydelig

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A isoenzymes. Metabolites are excreted in feces (78%) and urine (14%).

Half-life: 8.2 hr.

Time/Action Profile

( in progression-free survival†)

ROUTEONSETPEAKDURATION
PO2 mo6 mo10–12 mo

† Noted for CLL.

Patient/Family Teaching

Pronunciation

EYE-dela-li-sib